ML20205Q854
| ML20205Q854 | |
| Person / Time | |
|---|---|
| Site: | 03019521 |
| Issue date: | 03/10/1986 |
| From: | Thomas R NRC OFFICE OF INSPECTION & ENFORCEMENT (IE REGION V) |
| To: | |
| Shared Package | |
| ML20205Q860 | List: |
| References | |
| 50-19913-01, 50-19913-1, NUDOCS 8606050002 | |
| Download: ML20205Q854 (4) | |
See also: IR 05000199/2013001
Text
.
f
! NRCFr.rm 374 ,
(3 833
,
&
PAGE
1
OF
^ETT
4 _PAGESj
U.S. NUCLEAR REGULATORY CoMMISSloN
MATERIALS LICENSE Amendment No. 10
Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93 - 438), and Title 10
Code of Federal Regulations, Chapter I, Parts 30,31,32,33,34,35,40 and 70, and in reliance on statements and representations y
heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, ty
source, and special nuclear material designated below; to use such material for the purpose (s) and at the place (s) designated below; to E
deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This @
license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is :,
subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any g
- conditions specified below, l
g
i 1
Licensee iN
In accordance with letters 'N
dated March 4, 1986 lE
1. Ketchikan General Hospital 3. License number 50-19913-01 is amended in
its entirety to read as follows:!g
j
l
i
2. 3100 Tongass Avenue !l
Ketchikan, A!aska 99901 s
4. Expiration date January 31, 1987 E
1
5. Docket or g
Reference No. 030-19521 ,
'
6. Byproduct, source, and/or 7. Chemical and/or physical _8. Maximum amount that licensee i
special nuclear material s form 4may possess at any one time I
unde; this license N
,;a l
.
A. Any byproduct materidl A. Any radiopharmaceutical A.,:As necessary for uses
listed in Groups I and ~ listed in Groups I and 11 \ authorized in p
11 of Schedule A,. of Schedule A, Section ' Subitem 9.A. y
35.100 of'10 CFR 35'
~
Section 35.100 of ~
p
! _',
10 CFR 35 , H
', -
~ , i
B. Any byproduct material x B .' Any forn listed in Group 111' 11. ^f2curiesofeach I
listed in Group III-
~
of Schedule A, Section 35.100 byproduct material
l
of Schedule A, of-10 CFR<35 ," authorized in y
Section 35.100 of Subi tem 6.B. i
i
N
C. Any byproduct material * [C. Any C. 3 millicuries of each I
I
listed in Section 31.11(a) > byproduct material
of 10 CFR 31 -
authorized in h
-
Subitem 6.C. b
i
D. Xenon 133 D. Gas or gas in solution that D. 50 millicuries i
is the subject of an active jl
(i .e. , not wi thdrawn or y
terminated) "New Drug g
Application" (NDA) approved p
by FDA or an active (i.e., il
not withdrawn, terminated or I
on " clinical hold") " Notice of I
Claimed Investigational Exemption
for a New Drug" (IND) that has
f y
been accepted by FDA p
>
E. Phosphorus 32 E. foluble phosphate E. 10 millicuries N
lN
h
h
p
86060S0002 860310
-9 1 PDR ,
UaKTJMunafamCEUsusumuuMEDKTamam'iEOsD11@!gss2iELWJshsE'MhWK2r NAW@hATMEUF
~ -
_ _
_------wm-mmmsatsfEE111MMf2FIsep_4m*FN*sswwsunsrrancaan. wag
g-- ' Form 374----
l NRC .
2 4
'
U.S. NUCLEAR REGULATORY CoMMISSloN l pggg g, PAGES fI
I License number 'E
I 50-19913-01 N
" """
, UP LEM NTAR S E
30 9 1
, ,
g Amendment No. 10 W
I N
I N
N 9. Authorized use lN
I
N
q A. Any diagnostic procedure listed Groups I and II of Schedule A, Section 35.100 ly
l of Title 10, Code of Federal Regulations. (N
N !E
N B. Preparation and use of radiopharmaceuticals for any diagnostic procedure IJsted I
'
in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal !g
g Regulations.
$
1
l C.
.
%
-In vitro studies. .
.'
1
-
R
N $, k
D. For blood flow and pulmonary' function studies. '
l E. For treatment of polycythemia vera, leukemia and bone metastases. E
. g g
'
l E.
N CONDITIONS 15;
4 - -
lE:
q cr -
- g:
l 10. Licensedmaterial.'shallbeusedoni.yatKetchikahGeneralHospital,3100
g Tongass Avenue, Ketchikan, Alaska; '
+
'
!gj
i -
, ' ~ - . . . . - !>;
N 11. The licensee shall-comply' with the . provisions _of Title 10, . Chapter 1, Code of
-
'E;
R Federal Regulatio'us, Part "19, " Notices,; Instructions and Reports [to Workers; E!
I Inspections" and Part 20, " Standards for Protection Againsti Radiation".
g 12. Licensed material listed in Item 6.!above iscauthbrized for use b'y, or under the
' h
q supervision of, the4fo11owingiindividual(s) for'the ma'terials'and uses indicated: il
g- s
, E;
'
4 Zeke L. Ifendricks , M.D. - Groups I, II, and<III E!
l
g
In vitro studies -
Xenon 133 J
fgj
y , Phosphorus'32 as soluble phosphate for gj
'
q ' treatment of polycythemia vera, kj
i ' leukemia, and bone metastases IEl
, I
I
k
Arthur K. Ilarris, M.D. Groups I, II, and III ll
l In vitro studies g)
,
y Xenon 133 gl
l Phosphorus 32 as soluble phosphate for N
, I treatment of polycythemia vera, N
I leukemia, and bone metastases E
l ll
l 'Rl
l B
1 N
I i
l lN
I 'p
i I
I
l I
I
n lI
,,
k
I I)f
bm-mr-mrs_shidiaWWNC*MhiGDWhittsi.f2rJih2i0iLTJduQis0afaiDucs2ididsfW'#'u m M l
.
f NRC Porm 374A g -
m 5c_mritT3GETElmlElmHT3GE2IIL3
l I
.
U.S. NUCLEAR R gGULAToRY COMMISSloN
PAGE 3 og 4 PAGES
l License numtzt
fE
I 50-19913-01 il
l MATERIALS LICENSE 3,c y, , ,, g ,,,,,,,, ,, ,3,, 1
SUPPLEMENTARY SHEET
030-19521 l
1 N
l Amendment No. 10 i
N N
I R
I CONDITIONS N
13. For a period not to exceed sixty (60) days in any calendar year, a visiting
l physician is authorized to use licensed material for human use uader the terms !
I of this license, provided the visiting physician: lNE'
R l
(a) Has the prior written permission of the hospital's Administrator and its l
l
g Medical Isotopes Committee, and Ig
f
i IN
l (b) Isspecificallynamedasauser[6naNuclear:RegulatoryCommissionlicense I
i
g
authorizing human use, and- '
,
-
s
llEy
W (c) Performs only those- procedures for which he is specifically authorized by a H
g ,y
y Nuclear Regulatory Commission license, i + jg
W ,
-is l5
g The licensee shall maintain for inspection by the Commission,' copies of the jN
4 written permissionfspecified in, subitem (a) above andL of the license (s) il
M specified in subitems (b) and1(c) above. These records shall be. maintained for
N
five (5) years from.the time:the-licensee grants its permission.under '
subitem (a) above. - #
l .
(' ~ Y
The licensee is authorized to hold radioactive material with a physical
.
l 14. $
4 half-life of less;than 65 days for decay-in-storage before, disposal in ordinary
9
I
'
4 trash provided: --
I H ;
f
g
A. Radioactive vaatie to' be disposed of in-tl$1stmanner shall be held for decay
a minimum of ten'(10) half-lives. "
k
g
4 , s W
4 B. Prior to disposal.as normal waste,< radioactive-waste slall 3
be monitored to E
I determine that its' radioactivity cannot be distinguished from background i
E!
with typical low-level laboratory survey instruments. All radiation labels N
l'
g
N
will be removed or obliterated.
'
~ -
' -
f%
l C. Generator columns shall be segregated'so"that they may be monitored P
1 separately to ensure decay to background levels prior to disposal. {E
1 lN
j
l 15. Effluent from the xenon 133 charcoal trap shall be tested for the presence of
xenon 133 after every ten patient procedures, in order to assure that the device
f
g
is functioning properly and that filter saturation has not occurred.
f
l p
N N
N 16. The license shall include the reference standards described below when R
performing dose calibrator accuracy tests:
i i
g Dose Calibrator Reference Standards y
1 N
N Radionuclide Ac ti vi ty Calibration Accuracy !N
4 !i
N Cesium 137 90 microcuries or more Within i 5% fl
l Cobalt 57 One millicurie or more Within i 5% il
< l.
I if
I il
brs ww-esshw 7g m ,r-r-r,==EN
_ _ _ _ _ _
__
r==============_=*======~
g NRC Ferm 374A .
U.S. NUCLEAR REGULATORY COMMISSION
_"3
PAGE OF PAGES lI
l 1icense numb 2r .I
N 50-19913-01 !i
l MATERIALS LICENSE oocket or nererence number 'N
N SUPPLEMENTARY SHEET N
030-19521
I E.
W W
d Amendment No. 10 g
I t !
I ; :
CONDITIONS l
l I
l
q 170 Except as specifically provided otherwise in this license, the licensee shall
d conduct its program in accordance with the statements, representations, and j
4 procedures contained in the documents including any enclosures, listed below. ;
The Nuclear Regulatory Commission's regulations shall govern unless the j
l statements, representations and procedures in the licensee's application and
g !g
g correspondence are more restrictive than the regulations.
M _
ju
I A. Application dated October 27, 1981 , p
4 B. Model ALARA Program contained in' Appendix O ' _ H
I of Regulatory Guide 10.8.(Rev. 1) *
N
C. Letter dated July 28, 1983
l D. Letter dated September'29, 1983 l
g g
g E. Letter dated March 13, 1984 p
$ F. Telegram dated July 5, 1984 ,g
i G. Letter dated October 16, 1985 ^ ; ,
H. Letter dated November 19,l1985- ,
,
j l
y
1. Letter date.d December 20, 1985 , , i l
"
y J. Letter dated March 4,1986
N ,
d 18. The Radiation Protection Officer for 'the activities authorized by this license
d is Dr. Zeke L. Hendricks. I
I
4 ~
I s
-
N
n , , .
4
'
NI !
ij > i
q !
N , !
il j
i
( ,f.
I
i FOR THE U.S. NUCLEAR REGULATORY COMMISSION IP
d !E
N original signed by R. D. Thomas N
g Date March 10, 1986 By
j. R. D. Thomas, Chief g
l Nuclear Materials Safety Section g
N Region V l
4 E
I g i
I l'l
1 p
I >
I
i !pg
4 !g
ll
l N
I M
i !g
i 'n
I s
65LitwYw w 'i's2sm2sQrKT.zQswaMaBem TYacgMfir#2scr2m0#mWylwmXmisUiECE